Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Idarubicin and Cytarabine in MDS and AML
NCT02464657Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02464657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464657.